KCM
MDGL icon

Kornitzer Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Kornitzer Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,760
Closed -$4.47M – 523
2025
Q2 		$4.47M Hold
14,760
– – 0.09% 246
2025
Q1 		$4.89M Hold
14,760
– – 0.1% 229
2024
Q4 		$4.55M Buy
+14,760
New +$4.15M 0.09% 246

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Kornitzer Capital Management's MDGL Position: Q3 2025 in Review

Kornitzer Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 14,760 shares — an estimated $4.47M sold.

Kornitzer Capital Management first reported a position in MDGL in Q4 2024 and held it in 3 quarters. The position peaked at $4.89M in Q1 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Kornitzer Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kornitzer Capital Management sold 14,760 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $4.47M.
  • Kornitzer Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Kornitzer Capital Management's Madrigal Pharmaceuticals position peaked at $4.89M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Kornitzer Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.